Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
UNII J06Y7MXW4D
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.0010.001239%Not Available
Condition aggravated08.01.03.0040.003098%Not Available
Corneal opacity06.06.03.005--Not Available
Cough22.02.03.0010.001239%
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.007--
Deafness04.02.01.0010.002478%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.002--Not Available
Death08.04.01.0010.016109%
Dehydration14.05.05.0010.001859%
Delusion19.10.01.001--
Depressed level of consciousness17.02.04.0020.001239%
Diabetes mellitus14.06.01.001; 05.06.01.0010.003098%Not Available
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001239%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug ineffective08.06.01.0060.011276%Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.0010.001859%Not Available
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.001239%Not Available
Gastroenteritis yersinia07.19.03.012; 11.02.20.002--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.001859%Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages